Press Releases
Caprion Biosciences and HistoGeneX Unite Businesses to Create Global Leader in Immune Monitoring and Biomarker Development
Partnership Facilitated by Major Investment from Arsenal Capital Partners NEW YORK, July 31, 2019 – Caprion Biosciences (“Caprion”) and HistoGeneX announced today they have agreed to combine their respective businesses. The new partnership creates a global leader in...
Caprion Biosciences Expands its Global Biomarker and Immune Monitoring Franchise by Acquiring Serametrix Corporation
MONTREAL, QUEBEC (April 30, 2019) / CNW Telbec / Caprion Biosciences announced today that the company acquired Serametrix Corporation, a specialized provider of immune monitoring services headquartered in Carlsbad, California. Caprion plans to leverage the proprietary...
Serametrix MDSC Assay Being Utilized By Infinity Pharmaceuticals in the First Clinical Study to Prospectively Identify Patients With High Blood Levels of MDSCs
Serametrix MDSC Assay Being Utilized By Infinity Pharmaceuticals in the First Clinical Study to Prospectively Identify Patients With High Blood Levels of MDSCs First Patient Enrolled in IPI-549 Plus OPDIVO® MDSC-High Cohort in Infinity Pharmaceuticals...
Serametrix gains CLIA certification for MDSC-based blood test for predicting response to immunotherapy in cancer patients
Serametrix gains CLIA certification for MDSC-based blood test for predicting response to immunotherapy in cancer patients SAN DIEGO, California-Sept. 22, 2016. Serametrix has received CLIA approval for MDSC testing in cancer patients, it was announced...
MDSC-based Blood Test for Predicting Response to Cancer Therapy Commercialized by Serametrix
SAN DIEGO, CA, November 19, 2013 -- Serametrix Corporation has announced the launch of an important new blood test for cancer patients. The test measures a patient’s level of circulating Myeloid Derived Suppressor Cells (MDSCs) that are known to decrease...
Penn State Hershey and Serametrix to seek companion diagnostic for immunotherapy in pediatric cancers
SAN DIEGO, CA, April 16, 2012 -- Penn State Hershey Children’s Hospital and Serametrix will collaborate on developing a diagnostic test for predicting individual clinical response to a novel immune therapy for brain cancer, it was announced today. The...
OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
Biomarkers May Facilitate Patient Selection For Treatment of Melanoma, Merkel Cell Carcinoma or Cutaneous T-Cell Lymphoma with OMS ElectroImmunotherapy SAN DIEGO, CA, November 16, 2011 -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its...
©2019 Serametrix l US: +1-760-652-4060 l Europe: +44 (0)20 8973 3853 | info@serametrix.com